NICEVIVA
MONOGRAPH SPEC LATEST 2026

Butyrate (Short-chain FA)

DIGESTIVE · Evidence Monograph

Butyrate (Short-chain FA) is an evidence-graded digestive monograph evaluated across 22 peer-reviewed PubMed studies (1 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials, encompassing n = 29 cumulative participants). Current clinical evidence is rated GRADE Moderate (3.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) Moderate (3.0 / 4.0)
Indexed PubMed Studies 22 Studies
Meta-Analyses · Reviews 1 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 0 RCTs (0 Double-Blind)
Cumulative Participants n = 29
Reported Trial Dosages 40.00 g · 100 g · 23.6 g
Trial Duration Range 21 days · 14 days · 7 days
Reading Time ~11 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 22 indexed PubMed studies, GRADE Moderate).
  2. 02 Adults matching clinical trial dosing protocols (40.00 g · 100 g · 23.6 g) over a structured 21 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
liver (PubMed clinical endpoint)
gut (PubMed clinical endpoint)
01

What Is Butyrate (Short-chain FA) & Why Does Form Matter?

Butyrate (Short-chain FA) is classified under DIGESTIVE and has been investigated across 22 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (40.00 g, 100 g, 23.6 g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Butyrate (Short-chain FA) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (0 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Butyrate (Short-chain FA) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Butyrate (Short-chain FA) an overall evidence rating of GRADE Moderate (3.0 / 4.0) based on 22 PubMed studies: 1 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials (0 double-blind, n = 29 total participants).

Representative peer-reviewed findings include: • PMID:32921467 (2020) — "Meta-analysis of the relationship between milk trans-10 C18:1, milk fatty acids <16 C, and milk fat production." (Tools that allow a timely diagnosis of BH-MFD would improve nutritional management.) • PMID:28342600 (2017) — "Temporal changes in milk fatty acid distribution due to feeding different levels of rolled safflower seeds to lactating Holstein cows." (This study indicated that SS fed at 3 and 6% of DM had the potential to increase milk production and the CLA in milk, but with a corresponding increase in n-6 FA.) • PMID:25074701 (2015) — "Effects of pistachio by-products on digestibility, milk production, milk fatty acid profile and blood metabolites in Saanen dairy goats." (It was concluded that PBP can be used as forage in the diet of dairy goats without interfering with milk yield.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 40.00 g · 100 g · 23.6 g · 4.7 g over 21 days · 14 days · 7 days · 81 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Butyrate (Short-chain FA), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (40.00 g · 100 g · 23.6 g) and re-evaluate efficacy after 21 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (22 Studies) · 4 Quantitative Analyses

01
META-ANALYSIS Journal of dairy science (2020) PMID: 32921467 ↗
Meta-analysis of the relationship between milk trans-10 C18:1, milk fatty acids <16 C, and milk fat production.
Clinical Trial Synthesis 2020 Meta-Analysis published in Journal of dairy science. Key conclusion: Tools that allow a timely diagnosis of BH-MFD would improve nutritional management.
View Original PubMed Abstract ↓

The economic value of milk fat and its responsiveness to management strategies provides strong interest in maximizing milk fat production by minimizing occurrence of biohydrogenation-induced milk fat depression (BH-MFD) and maximizing de novo synthesized fatty acids (FA). Tools that allow a timely diagnosis of BH-MFD would improve nutritional management. Specific milk FA or FA categories correlate to milk fat concentration and are of interest for diagnosing the cause of changes in milk fat concentration. The objective of the current study was to characterize the relationship between milk fat concentration and trans-10 C18:1, a proxy for BH-MFD, and FA <16 carbons that originate solely from de novo lipogenesis using a meta-analysis approach that used data from the literature and unpublished Penn State experiments. Prior to the meta-analysis, the effect of FA methylation method on milk FA profile was tested to determine potential bias between papers. There was no difference between sodium methoxide, acid, and acid-base methylation methods on trans-10 C18:1 concentration, but acid methods resulted in loss of short-chain FA. The relationship between trans-10 C18:1 and milk fat percentage was investigated using a 2-component model, where one component described the fraction unresponsive to BH-MFD and the other described a responsive fraction that is exponentially related to trans-10 C18:1. The 2 fractions where characterized utilizing a Bayesian hierarchical model accounting for between-study variability. The model was defined by the function f(x, θ1, θ2, θ3) = θ1 + θ2exp(θ3), where the unresponsive θ1 fraction was 2.15 ± 0.09%, the responsive θ2 fraction was 1.55 ± 0.08%, and the exponential term θ3 was -0.503 ± 0.07 (posterior mean ± posterior standard deviation from the Bayesian hierarchical model). A Lin's concordance correlation coefficient of 0.67 suggested good agreement between observations and predictions from the Bayesian hierarchical model, computed only with the model's mean population parameters. There was a linear relationship between milk fat concentration and FA <16 C as a percentage of total FA (intercept = 2.68 ± 0.237 and slope = 0.043 ± 0.011; coe

02
CLINICAL STUDY Journal of dairy science (2017) PMID: 28342600 ↗
Temporal changes in milk fatty acid distribution due to feeding different levels of rolled safflower seeds to lactating Holstein cows.
Clinical Trial Synthesis 2017 Clinical Study published in Journal of dairy science. Key conclusion: This study indicated that SS fed at 3 and 6% of DM had the potential to increase milk production and the CLA in milk, but with a corresponding increase in n-6 FA.
View Original PubMed Abstract ↓

The objective of this experiment was to follow the time-course changes of the milk fatty acids (FA) and particularly conjugated linoleic acid (CLA), n-3, and n-6 FA in response to feeding whole rolled safflower seed (SS). Eighteen cows were blocked by milk production, days in milk, and parity, and randomly assigned to 1 of 3 diets by replacing whole cottonseed with SS. The control diet contained no SS (SS0), whereas the other diets contained 3% of dry matter as SS (SS3) or 6% SS (SS6). The study was conducted for 8 wk. Cows fed SS produced more milk than SS0, with SS3 producing more milk than SS6, but without a change in milk fat yield or milk fat %. Except for C8:0 FA, changes in milk FA were not observed until the third week of SS feeding. The C8:0 began decreasing during wk 1 of SS feeding and continued to decline to wk 8. Short-chain FA (C6:0 to C11:0) and medium-chain FA (C12:0 to C16:1) concentrations decreased in milk when cows were fed SS, whereas long-chain FA (C18:0 and higher) increased after wk 3. The milk long-chain FA increased from wk 3 until wk 5 and then reached a plateau with little difference between SS3 and SS6, whereas the short-chain FA decreased more in milk from cows fed SS6 than SS3. Total CLA increased slightly less than 5× in milk from cows fed SS compared with SS0. Over the same time frame, n-3 FA declined and n-6 FA increased in the milk from cows fed SS, with no difference between SS3 and SS6. This study indicated that SS fed at 3 and 6% of DM had the potential to increase milk production and the CLA in milk, but with a corresponding increase in n-6 FA.

03
CLINICAL STUDY Journal of animal physiology and animal nutrition (2015) PMID: 25074701 ↗
Effects of pistachio by-products on digestibility, milk production, milk fatty acid profile and blood metabolites in Saanen dairy goats.
Clinical Trial Synthesis 2015 Clinical Study published in Journal of animal physiology and animal nutrition; statistical significance reported at p = 0.01. Key conclusion: It was concluded that PBP can be used as forage in the diet of dairy goats without interfering with milk yield.
View Original PubMed Abstract ↓

The objective of this study was to investigate the effects of pistachio by-products (PBP) on nutrient digestibility, blood metabolites and milk fatty acid (FA) profile in Saanen dairy goats. Nine multiparous lactating Saanen goats (on day 90 post-partum, 45 ± 2/kg BW) were randomly assigned to a 3 × 3 Latin square design with three treatment diets: 1) control diet (alfalfa hay based), 2) 32% PBP and 3) 32% PBP + polyethylene glycol (PEG-4000; 1 g/kg dry matter). Each period lasted 21 days, including 14 day for treatment adaptation and 7 day for data collection. Pistachio by-products significantly decreased (p < 0.01) crude protein (CP) digestibility compared with the control diet (64.4% vs. 58.7%), but PEG addition did not differ for CP digestibility of goats fed 32% PBP + PEG and those fed the two other diets. The digestibility of NDF tended (p = 0.06) to decrease for goats fed PBP compared with those fed the control diet. Yields of milk and 4% fat-corrected milk were not affected by dietary treatments. Compared with the control diet, PBP supplementation appreciably changed the proportions of almost all the milk FA measured; the main effects were decreases (p < 0.01) in FA from 8:0 to 16:0 and increases (p < 0.01) proportions of cis-9, trans-11 18:2 and trans-11 18:1, monounsaturated FA, polyunsaturated FA and long-chain FA. The saturated FA, short-chain FA and medium-chain FA proportions were lower (p < 0.01) in goats fed the two PBP supplemented diet than in those fed the control diet and PEG addition led to intermediate proportions of saturated FA, unsaturated and monounsaturated FA. Inclusion of PBP in the diet decreased (p < 0.01) plasma concentrations of glucose and urea nitrogen compared with the control diet. It was concluded that PBP can be used as forage in the diet of dairy goats without interfering with milk yield. Inclusion of 32% PBP in the diet of dairy goats had beneficial effects on milk FA profile but PEG addition to PBP did not contribute to enhance further milk FA profile. Journal of Animal Physiology and Animal Nutrition © 2014 Blackwell Verlag GmbH.

04
CLINICAL STUDY Journal of ethnopharmacology (2026) PMID: 41839301 ↗
Spatial metabolomics reveals the therapeutic mechanisms of Shengjiang Xiexin decoction in modulating gut-liver axis fatty acid metabolism for the treatment of Clostridioides difficile infection.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of ethnopharmacology. Key conclusion: CONCLUSION: SXD ameliorates CDI-induced gut-liver injury through multiple pathways, including regulating gut-liver axis inflammatory responses, and FA metabolism.​ From a spatial perspective, this study achieved in situ characterization of SXD's mode of action, providing valuable
View Original PubMed Abstract ↓

ETHNOPHARMACOLOGICAL RELEVANCE: Shengjiang Xiexin Decoction (SXD) is a classic formula documented in the Treatise on Cold Damage and Miscellaneous Diseases. It has long been used to treat infectious gastrointestinal diseases characterized by diarrhea, dysentery, and abdominal distension. Its core pathogenesis involves spleen-stomach disharmony and damp-heat accumulation, consistent with clinical features of bacterial or viral enteritis. Although SXD effectively relieves gastrointestinal symptoms, its active components and mechanisms remain unclear, especially regarding spatial regulation of gut-liver axis metabolism. AIM OF THE STUDY: We aim to map the spatial landscape of gut-liver axis metabolism regulated by SXD in CDI-induced mice, by employing a strategy that combines whole-animal mass spectrometry imaging (MSI) technology with spatial metabolomics. METHODS: After CDI modeling and SXD intervention, intestinal injury was evaluated by biochemical and histopathological analysis. MSI was used for in situ detection of SXD active components, and spatial metabolomics to investigate its regulatory effects on gut-liver axis metabolic disorders. RESULTS: SXD attenuated colonic mucosal epithelial detachment and suppressed inflammation. MSI identified wogonin, glycyrrhizic acid, shogaol, gingerenone B, feruloyltyramine, and paradol as key active components targeting the gut-liver axis. Spatial metabolomics demonstrated that SXD reduced intestinal accumulation of medium- and long-chain fatty acids (MCFAs and LCFAs), alleviated hepatic metabolic imbalance characterized by excessive short-chain FA accumulation and MCFA/LCFA depletion, and restored FA homeostasis across the disrupted gut-liver axis. CONCLUSION: SXD ameliorates CDI-induced gut-liver injury through multiple pathways, including regulating gut-liver axis inflammatory responses, and FA metabolism.​ From a spatial perspective, this study achieved in situ characterization of SXD's mode of action, providing valuable information for investigating its material basis and mechanisms.

05
CLINICAL STUDY Journal of dairy science (2026) PMID: 41482044 ↗
A multivariate approach to exploring interrelationships among milk fatty acids across ruminant species.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of dairy science. Key conclusion: According to a previous study on MFA, a variable was considered to be associated with a specific factor if the absolute value of its correlation with the factor was ≥0.60.
View Original PubMed Abstract ↓

The milk fatty acid (FA) profile is influenced by complex interactions among animal species, physiology, feeding, and management, resulting in modification to the nutritional and functional properties of milk fat. This study aimed to identify latent biological and nutritional factors influencing milk FA composition in ruminants using multivariate factor analysis (MFA), applied across 4 species: dairy cows (Holstein-Friesian and Brown Swiss), sheep (Sarda and Massese), Mediterranean buffaloes, and goats (Saanen). A total of 1,960 mid-lactation animals (150 ± 16 DIM for cows; 90 ± 5 DIM for sheep; 162 ± 14 DIM for buffalo; 86 ± 3 DIM for goats), raised under commercial farm conditions and subjected to diverse feeding regimens, were included in the study. All milk samples were analyzed by the same laboratory using GC under consistent analytical conditions. Factor analysis was carried out on 49 individual FA. An ANOVA on the factor scores was performed to assess the effects of species and feeding strategies, specifically lipid supplementation in cow milk and n-3 supplementation in sheep milk. The MFA was able to extract 7 latent factors with specific biologic meaning: synthesis of odd- and branched-chain fatty acids from ruminal bacteria (factor 1: "OBCFA"), de novo FA synthesis via acetate in mammary gland (factor 2: "Mammary activity"), biohydrogenation of linoleic acid (factor 3: "BH_1"), milk fluidity regulation (factor 4: "Milk fluidity"), mitochondrial Beta-oxidation of FA (factor 5: "Beta-oxidation"), biohydrogenation via vaccenic acid (factor 6: "BH_2"), ruminal 16:1c7 elongation (factor 7: "16:1c7 elongation"), regulation of branched (factor 8: "BCFA") and odd (factor 9: "OCFA") chain FA, n-6 metabolism (factor 10: "n-6 FA"), and synthesis of short-chain FA (factor 11: "SCFA"). According to a previous study on MFA, a variable was considered to be associated with a specific factor if the absolute value of its correlation with the factor was ≥0.60. Several factors reflected established metabolic processes, such as "OBCFA," "Mammary activity," and "BH_1." Others, such as "Beta-oxidation" and "16:1c7 elongation," captured novel pathways not previously described

06
CLINICAL STUDY Journal of dairy science (2025) PMID: 40701512 ↗
Effect of dietary palmitic acid supplementation and milking frequency: 2. Butter manufacture and properties.
Clinical Trial Synthesis 2025 Clinical Study published in Journal of dairy science. Key conclusion: Resistance to spreadability increased with PA at both 4°C and 20°C.
View Original PubMed Abstract ↓

Dietary palmitic acid (PA) supplementation promotes fat yield, whereas increased milking frequency (MF) enhances milk yield. Such practices can be useful at the farm level, but their effects on milk processing remain to be determined. The objective of this study was to evaluate the effects of dietary PA supplementation and increased MF from 2 times to 3 times daily on butter manufacture and properties. In a duplicated 4 × 4 Latin square design, with a 2 × 2 factorial arrangement of treatments, 8 Holstein cows received a diet with or without PA (2% or 0%, on a DM basis) and were milked 2 times or 3 times daily. For each period, after 18 d of treatment adaptation, milk was collected from each cow for 2 d, and pooled by treatment before butter manufacture. Milk free fatty acids (FA) concentration and casein micelle size were similar between treatments, as well as cream fat globule diameter and butter yield. There was a significant interaction between PA and MF on churning time. With the nonsupplemented diets, 3 times daily milking increased churning time, and with 2 times daily milking, PA supplementation also increased churning time. Butter FA composition was mostly affected by PA, whereas MF had a limited effect. Total 16 C FA concentration in butter was increased with dietary PA at the expense of short-chain FA (6-14 C) and, to a lesser extent, long-chain FA (≥18 C). Dietary PA increased butter hardness at 20°C, whereas this effect was limited to a tendency when measured at 4°C. Resistance to spreadability increased with PA at both 4°C and 20°C. Overall, the effects of PA on butter texture were less pronounced at 4°C than at 20°C. Milking frequency had no effect on butter texture. Butter melting point was greater with PA and was positively correlated with the concentration in 16:0 and the spreadability index (cis-9 18:1/16:0). The solid fat content of butter was similar between PA and non-PA treatments at 5, 8, and 20°C. However, from 30°C, the solid fat content was higher with the PA diet. The spreadability index was correlated with butter hardness, and to a greater extent, with butter spreadability. This work underscores how dairy farm management influences th

07
CLINICAL STUDY Journal of dairy science (2025) PMID: 40306432 ↗
Fatty acid fingerprint enables linking forage and milk composition in assessing the geographical origin of Chinese Holstein cow milk.
Clinical Trial Synthesis 2025 Clinical Study published in Journal of dairy science. Key conclusion: The observed variations in milk FA are primarily influenced by forage FA, providing valuable insights for improving milk quality through better forage management.
View Original PubMed Abstract ↓

This study aimed to assess the effectiveness of fatty acid (FA) fingerprinting in distinguishing the geographical origin of milk and linking milk FA profiles with those of forage. A total of 66 bulk-tank milk samples and 66 corresponding forage samples were collected over 3 consecutive days from 22 dairy farms across western, eastern, and southern China. The FA compositions of the samples were analyzed using GC-MS, identifying 81 individual FA. Using orthogonal partial least squares discriminant analysis and significance analysis, we identified significant regional differences in the 35 milk FA. Recursive feature elimination was used to identify 10 potential FA biomarkers for the geographical origin of milk, including C18:2 cis-9,trans-12, C18:1 trans-6, PUFA, C18:1 cis-12, C20:3 cis-8,cis-11,cis-14, C14:0, MUFA, C13:0 iso, C16:1 cis-9, and C13:0. A support vector machine model based on these 10 biomarkers classified the milk samples by region with an accuracy >95%. Canonical and Spearman's correlation analyses indicated relationships between milk and forage FA profiles. Specifically, milk FA such as C13:0 iso, C13:0, C14:0, and C16:1 cis-9 showed significant positive correlations with most short-chain FA, odd-chain SFA, and branched-chain SFA in the forage and negative correlations with long-chain FA and FA greater than C16. Conversely, milk FA C18:2 cis-9,trans-12, C18:1 trans-6, and C18:1 cis-12 exhibited the opposite trend. The correlation between UFA in milk and forage was more complex, showing both positive and negative relationships. These findings demonstrate that FA fingerprinting is a reliable method for determining the geographical origin of milk. The observed variations in milk FA are primarily influenced by forage FA, providing valuable insights for improving milk quality through better forage management. The Authors. Published by Elsevier Inc. on behalf of the American Dairy Science Association®. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

08
CLINICAL STUDY Veterinary and animal science (2025) PMID: 39817032 ↗
Productive performance, rumen parameters, carcass quality, antioxidant profile and methane emission in lambs supplemented with triticale hay.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Veterinary and animal science; statistical significance reported at p = 0.01. Key conclusion: Overall, TH can be included, up to 40 % of DM in the diet of fattening lambs, without effects on performance, to improve carcass quality, FA composition, and antioxidant capacity and reduce ruminal methane production.
View Original PubMed Abstract ↓

This study aims to measure the effects of different dietary concentrations of triticale hay (TH) on productive performance, carcass characteristics, microbial protein synthesis (MPS), ruminal and blood variables, and antioxidant power in 40 fattening male Gray Shirazi lambs (BW of 33.2 ± 1.1 kg) over 81 days in a completely randomized design (10 animals/diet). Four levels of TH (0.00, 13.30, 26.50, and 40.00 g/100 g dry matter; DM) were included in the diet, instead of alfalfa hay + barley straw. Dietary inclusion of TH decreased DM and nutrient intakes, but increased phenolic and flavonoid intakes, and digestibility of DM and nutrients (L, P < 0.01). Feeding TH did not affect daily gain, feed conversion ratio, carcass weight, dressing percentage, and Longissimus muscle area, decreased (L, P < 0.05) fat-tail, total carcass fat, and carcass stearic acid but increased (L, P < 0.05) lean-to-total carcass fat ratio, carcass oleic acid, polyunsaturated fatty acids (FA), and antioxidant power. Dietary TH increased ruminal MPS and cellulolytic bacteria but decreased ammonia-N, protozoa, and in vitro methane production (L, P < 0.01). Nitrogen retention and rumen short-chain FA were not affected by TH addition. Increasing dietary TH levels lowered (L, P < 0.01) blood cholesterol, triglyceride, and urea-N, but did not affect glucose, total protein, albumin, globulin, nitrate, and nitrite. Overall, TH can be included, up to 40 % of DM in the diet of fattening lambs, without effects on performance, to improve carcass quality, FA composition, and antioxidant capacity and reduce ruminal methane production. © 2024 The Author(s).

09
CLINICAL STUDY Clinica chimica acta; international journal of clinical chemistry (2025) PMID: 39581249 ↗
Fecal fatty acid-linked bile acid profiles in pediatric patients with ulcerative colitis.
Clinical Trial Synthesis 2025 Clinical Study published in Clinica chimica acta; international journal of clinical chemistry. Key conclusion: CONCLUSION: The present study reported the fecal FA-isoBA profiles in pediatric UC patients for the first time.
View Original PubMed Abstract ↓

OBJECTIVE: Effect of gut dysbiosis on fatty acid (FA) linked 3β-hydroxy-bile acid esters (FA-isoBAs) formation is currently unknown. This study aimed to investigate the profile of FA-isoBAs in fecal samples from pediatric patients with ulcerative colitis (UC). METHODS: Fecal samples were collected from seven pediatric patients diagnosed with UC and seven age-matched healthy controls. Liquid chromatography-tandem mass spectrometry (LC/MS) method was set up for quantifications of thirteen different FA-isoBAs, including three new FA-isoBAs which had never been characterized. Method validation tests were performed with optimization of sample preparation. Statistical analyses were conducted to compare FA-isoBA concentrations between UC patients and healthy controls. RESULTS: The LC/MS method had sufficient linearity (r > 0.998), with the low detection limit (0.03-2.82 nmol/g stool), and limits of quantification (0.10-9.40 nmol/g stool) for all FA-isoBAs. The total FA-isoBAs concentration in UC patients was significantly lower than healthy controls, regardless of the degree of the disease severity. The UC subjects had markedly increased primary bile acid (BA) levels with decreased secondary BAs. Propionic acid-linked isoBA and stearic acid-linked 12-oxo-isolithocholic acid were newly identified from healthy subjects but they were not present in UC subjects. In agreement with the previous report, composition of long-chain (C16-C18) FA-linked BAs dominated over short-chain FA-linked BAs both in healthy and disease subjects. CONCLUSION: The present study reported the fecal FA-isoBA profiles in pediatric UC patients for the first time. The results open the door to the new field that investigates the role of these microbial-driven BAs in gastrointestinal health.

10
CLINICAL STUDY Scientific reports (2024) PMID: 38503819 ↗
Antibiotics and probiotics-induced effects on the total fatty acid composition of feces in a rat model.
Clinical Trial Synthesis 2024 Clinical Study published in Scientific reports. Key conclusion: Changes in short chain FA (SCFA) composition are associated with gut microbiota modifications.
View Original PubMed Abstract ↓

Fatty acids (FAs) play important roles as membrane components and signal transduction molecules. Changes in short chain FA (SCFA) composition are associated with gut microbiota modifications. However, the effect of bacteria-driven changes on the detailed FA spectrum has not been explored yet. We investigated the effect of antibiotics (ABx) and/or probiotics, in four treatment groups on rat stool FA composition. Principal component analysis indicated that the chromatogram profiles of the treatment groups differ, which was also observed at different time points. Linear mixed effects models showed that in the parameters compared (sampling times, treatments. and their interactions), both the weight percentage and the concentration of FAs were affected by ABx and probiotic administration. This study found that the gut microbiome defines trans and branched saturated FAs, most saturated FAs, and unsaturated FAs with less carbon atoms. These results are among the first ones to demonstrate the restoring effects of a probiotic mixture on a substantial part of the altered total FA spectrum, and also revealed a previously unknown relationship between gut bacteria and a larger group of FAs. These findings suggest that intestinal bacteria produce not only SCFAs but also other FAs that may affect the host's physiological processes. © 2024. The Author(s).

RELATED MONOGRAPHS

Related Monographs in This Category